Navigation Links
Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
Date:5/7/2008

FREDERICK, Md., May 7 /PRNewswire/ -- Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path to more than $100 million of potential European sales.

The Dutch approval of the company's facility based in Emmen, The Netherlands also paves the way to its pivotal US FDA Phase IIIb clinical trial -- the final step before the vaccine can be sold in the United States.

"The facility can produce up to 3,500 vaccines annually, equivalent to $130 million in revenues," said Michael G. Hanna, Jr., Ph.D., Vaccinogen CEO. "That number only scratches the surface of potential demand for a Stage II colon cancer vaccine. One of every three patients who have their cancer removed see it return -- and the results are usually fatal."

"Our experience with OncoVAX has resulted in increasing the patients' chance of survival by more than 50%," he concluded. "This represents an opportunity for a new lease on life for tens of thousands of patients around the world."

The Dutch license permits the company to commercialize the vaccine, first in Switzerland and then in seven other countries in Eastern Europe. The OncoVAX vaccine represents a potential medical breakthrough because it uses a patient's own cancer cells to prevent the cancer from returning after a successful operation to remove it.

"This manufacturing license being granted by the most stringent and respected biotech manufacturing reviewers in Europe is a major milestone for Vaccinogen as it begins to generate revenues from OncoVAX," Dr. Hanna said. "It's also a major leap towards the worldwide acceptance of individualized cancer vaccines."

About OncoVAX

OncoVAX immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.

About Vaccinogen

Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products -- Turning Cancer on Itself(TM). Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development.

http://www.vaccinogeninc.com

Vaccinogen's online press kit: http://www.vaccinogeninc.com/press_kit.cfm

Contact:

Andrew L. Tussing

Vaccinogen

atussing@vaccinogeninc.com

301-668-8400


'/>"/>
SOURCE Vaccinogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Highly Promising Dutch Research Into Alzheimers Disease and Parkinsons Disease
2. AOA President Calls on Congress to Reauthorize SCHIP and Take Action to Ensure Health Care Coverage for All Americans
3. Childrens Hospitals in Washington to Lobby Congress to Reauthorize SCHIP Now
4. American Physicians Capital, Inc. Authorizes Additional $20 Million Share Buyback
5. QLT Board authorizes exploration of strategic alternatives to enhance near- to mid-term shareholder value
6. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
7. Aflac Incorporated to Accelerate Share Repurchase in 2008; Authorizes Additional Share Repurchase and Increases Quarterly Cash Dividend 17.1%
8. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
9. Congress Poised to Reauthorize Legislation Aimed at Dramatic Expansion of Global HIV and AIDS Programs
10. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
11. 5,000 Northern California Nurses to Vote to Authorize Third Strike Against Sutter Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA ... does not obey the rules Congress has directed the CBO to follow. The CBO ... reform would restore. Yet, it estimates a reduction in employer-based coverage due to the ...
(Date:3/24/2017)... Diego, Calif. (PRWEB) , ... March 24, 2017 ... ... has raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... the instant demand for the product – with nearly 2,000 consumers (and counting) ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National Council ... programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT requirements ... quality in the U.S. It argues that this higher bar should be set by ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... cannabis products around the world are projected to gain popularity. A report ... will reach a value of USD 55.8 billion by 2025. ... industry. By the end of 2016, 28 states have now laws and ... states like Arkansas and North Dakota ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: